Sandaracopimaric acid against the MAO-B/LRRK2 axis in Parkinson’s disease

Résumé

Abstract Parkinson’s disease lacks disease-modifying therapies; MAO-B inhibition remains a symptomatic standard, whereas LRRK2 kinase is a genetically validated Parkinson’s disease target. Here, the resin-acid diterpene sandaracopimaric acid (SCP) was evaluated as a CNS-oriented, hypothesis-generating scaffold rather than as a validated inhibitor. SwissADME predicted high gastrointestinal absorption, blood-brain barrier permeation and non-substrate behavior toward P-gp, with low aqueous solubility as the main developability limitation; ProTox-III suggested low acute oral toxicity (LD 50 approximately 20,000 mg·kg⁻¹; class 6). Redocking-validated docking to MAO-B (2V5Z; RMSD = 1.068 Å), LRRK2 (8FO7; RMSD = 1.693 Å), along with a complementary MAO-A selectivity counter-screen (2Z5X; RMSD = 0.270 Å) supported an MAO-B-favouring profile for SCP (-7.9 kcal·mol⁻¹) compared with LRRK2 (-6.9 kcal·mol⁻¹) and MAO-A (-6.2 kcal·mol⁻¹). In 100-ns GROMACS simulations, SCP remained more compactly retained in MAO-B than in LRRK2. MM/GBSA and PCA further supported a more favorable, single-basin MAO-B recognition pattern, whereas LRRK2 displayed a more solvent-exposed and flexible regime. Overall, SCP stands out computationally as an MAO-B-preferring natural scaffold ripe for experimental follow-up, where MAO-A/B enzymatic selectivity testing and LRRK2 kinase assays will serve to validate its true therapeutic viability.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0